The success of personalized medicine in oncology relies on using highly effective and
precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal …

Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in
clinical results and on the market. At the same time, success drives more attention from …

Cancer immunotherapy has shown remarkable progress in recent years. Nanocarriers, such
as liposomes, have favorable advantages with the potential to further improve cancer …

Hypoxia is a common feature of the tumor microenvironment, which is characterized by
tissue oxygen deficiency due to an aggressive proliferation of cancer cells. Hypoxia …

Immunotherapy continues to be in the spotlight of oncology therapy research in the past few
years and has been proven to be a promising option to modulate one's innate and adaptive …

The delivery of chemotherapeutics to solid tumors using smart drug delivery systems
(SDDSs) takes advantage of the unique physiology of tumors (ie, disordered structure, leaky …

Biological macromolecule-based therapeutics irrupted in the pharmaceutical scene
generating a great hope due to their outstanding specificity and potency. However, given …

Lipid nanoparticles (LNPs) are biocompatible drug delivery systems that have found
numerous applications in medicine. Their versatile nature enables the encapsulation and …

During the past two decades, the clinical use of biopharmaceutical products has markedly
increased because of their obvious advantages over conventional small-molecule drug …

Immunotherapy has significantly improved cancer treatment, yet the immunosuppressive
tumor microenvironment (TME) remains a substantial impediment to therapeutic efficacy …